New data suggest there is substantial diagnostic delay in people with young-onset Alzheimer’s disease (AD), including delays in referral and in the analysis of CSF biomarkers.
At the EAN 2021 virtual conference, researchers from the Norwegian University of Science and Technology, and the Nord-Trondelag Hospital Trust, in Trondheim, Norway, presented findings from the largest study of its kind, investigating delays in AD diagnosis in patients under 65 years of age.